| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2012 | US8119656 Inhibitors of the influenza virus non-structural 1 protein |
| 02/21/2012 | US8119655 Kinase inhibitors |
| 02/21/2012 | US8119654 Indenoisoquinolinone analogs and methods of use thereof |
| 02/21/2012 | US8119653 Belactosin derivatives as therapeutic agents/biological probes and their synthesis |
| 02/21/2012 | US8119652 Aryl-fused spirocyclic compounds |
| 02/21/2012 | US8119651 Compositions useful especially for treatment or prevention of metabolic syndrome |
| 02/21/2012 | US8119650 Aminophenyl derivatives as novel inhibitors of histone deacetylase |
| 02/21/2012 | US8119649 Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
| 02/21/2012 | US8119648 Arthritis, obesity, (non-insulin dependent) diabetes calcitonin-induced osteoporosis; administering allograft transplantation; dipeptidyl peptidase-IV (DPP-IV) inhibitors |
| 02/21/2012 | US8119647 Fused pyrimidineone compounds as TRPV3 modulators |
| 02/21/2012 | US8119646 Fungicide hydroximoyl-tetrazole derivatives |
| 02/21/2012 | US8119645 Fungicide hydroximoyl-tetrazole derivatives |
| 02/21/2012 | US8119644 Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| 02/21/2012 | US8119643 Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| 02/21/2012 | US8119642 Structurally rigid dopamine D3 receptor selective ligands and process for making them |
| 02/21/2012 | US8119641 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors |
| 02/21/2012 | US8119640 Hedgehog pathway antagonists methods of use |
| 02/21/2012 | US8119639 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile |
| 02/21/2012 | US8119638 Compositions and uses of ET743 for treating cancer |
| 02/21/2012 | US8119637 Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor |
| 02/21/2012 | US8119636 Pyrrolopyrazine kinase inhibitors |
| 02/21/2012 | US8119635 Diazabicyclic central nervous system active agents |
| 02/21/2012 | US8119634 Dual-acting pyrazole antihypertensive agents |
| 02/21/2012 | US8119633 Substituted sulfonamide compounds |
| 02/21/2012 | US8119632 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| 02/21/2012 | US8119631 Inhibitors of interleukin-1β converting enzyme |
| 02/21/2012 | US8119629 Carboxamide GABAA α2 modulators |
| 02/21/2012 | US8119628 Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors |
| 02/21/2012 | US8119627 Heterocyclic compounds as inhibitors of 17beta-HSD3 |
| 02/21/2012 | US8119626 Oxime derivative and preparations thereof |
| 02/21/2012 | US8119625 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 02/21/2012 | US8119624 Fused phenyl amido heterocyclic compounds |
| 02/21/2012 | US8119623 Pyrrolidin-2-ones |
| 02/21/2012 | US8119622 7-phenyl-substituted tetracycline compounds |
| 02/21/2012 | US8119621 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| 02/21/2012 | US8119620 Containing a specific number of progesterone-containing daily units A and a specific number of progesterone-containing daily units B for uninterrupted, daily, oral administration; units A contain at most 200 mu g folic acid; units B contain more than 200 mu g folic acid |
| 02/21/2012 | US8119619 Pregnane steroids and their use in the treatment of CNS disorders |
| 02/21/2012 | US8119618 Compositions and methods for the treatment of inflammatory diseases |
| 02/21/2012 | US8119617 aSMase inhibitors |
| 02/21/2012 | US8119616 Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| 02/21/2012 | US8119615 Incubating in an aqueous solution of a sugar polymer or sugar polymer derivative, such as inulin derivatized with urethane groups; improves yield of native protein in genetic engineering |
| 02/21/2012 | US8119614 Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 02/21/2012 | US8119612 RNAi inhibition of alpha-ENaC expression |
| 02/21/2012 | US8119611 Treatment of neurodegenerative disease through intracranial delivery of SIRNA |
| 02/21/2012 | US8119610 Methods of making RNAi libraries using E. coli RNAse III for inhibition of mammalian gene expression |
| 02/21/2012 | US8119609 Apoptosis and increased production of ceramides and DAG are normalized in the presence of antioxidants |
| 02/21/2012 | US8119608 Specific inhibition of expression of target gene in mammals using short double stranded RNA; dsRNA less than 49 nucleotides in length, has nucleotide sequence complementary to part of target gene; treating cancer, Alzheimer's disease |
| 02/21/2012 | US8119607 Bicyclic nucleosides and nucleotides as therapeutic agents |
| 02/21/2012 | US8119596 Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
| 02/21/2012 | US8119590 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally |
| 02/21/2012 | US8119563 N-substituted azacycles |
| 02/21/2012 | US8119405 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 02/21/2012 | US8119397 Therapeutic agents and therapeutic methods for treating injured tissue |
| 02/21/2012 | US8119180 Method for maintaining freshness of fruits and vegetables |
| 02/21/2012 | US8119168 Topical antidandruff agents comprising mixtures of group IIB compounds such as zinc pyrithione, zinc oxide or calamine |
| 02/21/2012 | US8119167 Food supplement composition suitable for promoting iron absorption |
| 02/21/2012 | US8119166 Methods of treatment using a gastric retained gabapentin dosage |
| 02/21/2012 | US8119163 Nanoparticulate and controlled release compositions comprising cefditoren |
| 02/21/2012 | US8119158 Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| 02/21/2012 | US8119155 Nutrition with lipids and non-digestible saccharides |
| 02/21/2012 | US8119154 Sustained release intraocular implants and related methods |
| 02/21/2012 | US8119148 Oxcarbazepine suspension; oral administering |
| 02/21/2012 | US8119142 Infant nutritional compositions for preventing obesity |
| 02/21/2012 | US8119138 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 02/21/2012 | US8119125 Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides |
| 02/21/2012 | US8119121 Delivering a concentrated amount of stem cells obtained from adipose tissue to a patient |
| 02/21/2012 | US8119116 Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| 02/21/2012 | US8119115 Antiviral method |
| 02/21/2012 | US8119113 Coenzyme Q10—containing composition |
| 02/21/2012 | US8119112 Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid |
| 02/21/2012 | US8119111 Topical administration carrier composition and therapeutic formulations comprising same |
| 02/21/2012 | US8118768 Drug eluting ocular implant with anchor and methods thereof |
| 02/21/2012 | CA2682254C 1,3-oxathiolane nucleoside analogues |
| 02/21/2012 | CA2663984C Biaryl ether urea compounds |
| 02/21/2012 | CA2659184C Ep2 agonists |
| 02/21/2012 | CA2650399C Gpr119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
| 02/21/2012 | CA2633077C Solid-state form of amg 706 and pharmaceutical compositions thereof |
| 02/21/2012 | CA2610794C Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same |
| 02/21/2012 | CA2610211C Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
| 02/21/2012 | CA2544136C Use of agomelatin in the formulation of drugs for the treatment of bipolar disorders |
| 02/21/2012 | CA2540109C Method for stabilization of diarylvinylene compounds |
| 02/21/2012 | CA2536787C Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
| 02/21/2012 | CA2534105C Aminoquinoline derivatives and their use as adenosine a3 ligands |
| 02/21/2012 | CA2529531C Stable 5,10-methylene-tetrahydrofolate pharmaceutical compounds |
| 02/21/2012 | CA2529207C 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same |
| 02/21/2012 | CA2528784C Hexahydropyridoisoquinolines as dpp-iv inhibitors |
| 02/21/2012 | CA2524726C Heterocyclyl-substituted dihydroquinazolines and use thereof as an antiviral agent |
| 02/21/2012 | CA2524091C Pharmaceutical formulation of the telmisartan sodium salt |
| 02/21/2012 | CA2512797C Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
| 02/21/2012 | CA2508845C Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
| 02/21/2012 | CA2508618C Tetrahydro-naphthalene derivatives |
| 02/21/2012 | CA2504610C Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
| 02/21/2012 | CA2503215C Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist |
| 02/21/2012 | CA2488372C Pyridazine derivatives which are phosphodiasterase iv inhibitors |
| 02/21/2012 | CA2487362C Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 02/21/2012 | CA2478542C Aminoindazole derivatives, their method of preparation and intermediaries of this process as medicines and pharmaceutical compositions containing same |
| 02/21/2012 | CA2472432C Soft tablet containing high molecular weight cellulosics |
| 02/21/2012 | CA2472399C Pharmaceutical compositions comprising valsartan and nep inhibitors |
| 02/21/2012 | CA2468933C Method for obtaining oestrogen from mare's urine |
| 02/21/2012 | CA2451981C 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |